MorphoSys Initiates Phase 2/3 Trial of CD19 Antibody MOR208 plus Bendamustine in Patients with Relapsed or Refractory DLBCL | Traderszone

- Home
- TZ Newswire
- Business Features
- ETF's
- Futures
- Options
- Real Estate
- Stocks
- TZ Featured Lists
- TZ Latest News
- TZ Resources
Editorial Archives
Editorial Archives

Published in TZ Latest News 5 September, 2016 by The TZ Newswire Staff

MorphoSys Initiates Phase 2/3 Trial of CD19 Antibody MOR208 plus Bendamustine in Patients with Relapsed or Refractory DLBCL

See also
- Next Article Orphan Drug Designation in European Union for GLPG1690 in idiopathic pulmonary fibrosis
- Previous Article Forex option expiries for the 10 am (14.00GMT) New York cut 6 September 2016
Editorial Calender

September 2016

M T W T F S S

1 2 3 4

5 6 7 8 9 10 11

12 13 14 15 16 17 18

19 20 21 22 23 24 25

26 27 28 29 30

« Aug Oct »
Recent Tags

Abnormal Returns Active management Asia Brave New World Business Chart.ly Chicago Board Options Exchange CNBC Commodities and Futures Covestor Day Trading Derivatives Equities Exchange Exchange-traded fund Funds Gawker.com GDP Gold Gold as an investment Gross domestic product High-frequency trading Hong Kong Investing Japan Market maker May 6 2010 flash crash Mutual fund National Association of Home Builders New York Mercantile Exchange Option S&P 500 SEC Standard & Poor Stock Stocks and Bonds Stock trader StockTwits Timothy Sykes Tokyo Trade Twitter U.S. Dollar Index U.S. Securities and Exchange Commission United States dollar